Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial
Table 2
Demographic characteristics of study participants.
Sugammadex
Neostigmine
Age (years) mean (SD)
57+/−7
58+/−7
Female sex (n/total)
68% (13/19)
45% (5/11)
ASA class (n/total)
1
11% (2/19)
9% (1/11)
2
68% (13/19)
55% (6/11)
3
21% (4/19)
36% (4/11)
4
0% (0/19)
0% (0/11)
Height (cm)
165+/−4
171+/−6
Weight (kg)
78+/−8
81+/−18
BMI
28+/−2
28+/−5
Current smoker (n/total)
5% (1/19)
9% (1/11)
Duration of surgery (min)
197+/−25
204+/−51
Relaxant used (n/total)
Rocuronium
21% (4/19)
45% (5/11)
Vecuronium
79% (15/19)
55% (6/11)
PONV prophylaxis (n/total)
None
0% (0/19)
18% (2/11)
Dexamethasone
26% (5/19)
18% (2/11)
Ondansetron
11% (2/19)
27% (3/11)
Dexamethasone/ondansetron
58% (11/19)
36% (4/11)
Dexamethasone/droperidol
5% (1/19)
0/11 (0/11)
ARISCAT risk score (n/total)
Low
33% (6/18)
27% (3/11)
Intermediate
67% (12/18)
45% (5/11)
High
0% (0/18)
27% (3/11)
Apfel risk score (n/total)
Minimal
0% (0/19)
0% (0/11)
Low
16% (3/19)
36% (4/11)
Intermediate
74% (14/19)
64% (7/11)
High
11% (2/19)
0% (0/11)
Very high
0% (0/19)
0% (0/11)
one patient had no preoperative Hb, therefore could not calculate ARISCAT score. SD, standard deviation; ASA, American society of anesthesiologists; ARISCAT, assess respiratory risk in surgical patients in Catalonia, BMI, body-mass index, PONV, postoperative nausea and vomiting.
